CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

Hongjie Wanga Department of Medicine, University of Washington, Seattle, WA, USAView further author information

Theo Kooba Department of Medicine, University of Washington, Seattle, WA, USAView further author information

Jonathan R. Frommb Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USAView further author information

Ajay Gopala Department of Medicine, University of Washington, Seattle, WA, USAView further author information

Darrick Carterb Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USAView further author information

André Liebera Department of Medicine, University of Washington, Seattle, WA, USA;b Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA;c R&D, Compliment Corp, Seattle, WA, USACorrespondence[email protected]

https://orcid.org/0000-0001-6742-6266 View further author information

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date